|
|
阿替利珠单抗联合贝伐珠单抗治疗肝细胞癌的现况
|
Abstract:
肝细胞癌(简称肝癌)是高发的恶性肿瘤，据国家癌症中心报告，截至2022年，在所有恶性肿瘤的发病率中，肝癌发病率位居第四。中国虽为乙肝大国，但我国肝癌的早期诊断率低，仅有不到30%的患者具备根治性手术的机会，大多数肝癌患者在初诊时已属中晚期(中国肝癌分期IIb期、IIIa期、IIIb期)。针对中晚期肝癌，系统抗肿瘤治疗是重要的治疗手段。近年来随着免疫检查点抑制剂联合靶向药物的应用，肝癌患者的总生存期得到显著提高，其中代表药物阿替利珠单抗(atezolizumab, A) + 贝伐珠单抗(bevacizumab, T)治疗方案(A + T方案)已被国内外多个指南推荐作为既往未接受过系统治疗的不可切除肝癌的一线治疗方案。本文将对A + T方案治疗肝癌的现况进行阐述。
Hepatocellular carcinoma (liver cancer) is a high incidence of malignant tumors, with the fourth highest incidence of liver cancer as of 2022, according to the National Cancer Center. Although China is a big country with hepatitis B, the early diagnosis rate of liver cancer in China is low, and only less than 30% of the patients have the opportunity of radical surgery. Most of the liver cancer patients with initial diagnosis are in the middle and advanced stage (China liver cancer staging IIb, IIIa and IIIb). Systematic anti-tumor therapy is an important treatment method for middle and advanced liver cancer. In recent years, with the application of immune checkpoint inhibitors combined targeted drugs, the overall survival of liver cancer patients was significantly improved, the representative drug atezolizumab + bevacizumab treatment (A + T regimen) has been recommended multiple guidelines at home and abroad as previously not received systemic treatment of unresectable liver cancer. This paper will describe the current status of A + T regimen.
| [1] | 胡晓云, 陈锦章, 王森锐. 阿替利珠单抗联合贝伐珠单抗与索拉非尼应用于不可切除肝细胞癌的疗效对比[J]. 循证医学, 2021, 21(6): 325-328, 336. |
| [2] | Gordan, J.D., Kennedy, E.B., Abou-Alfa, G.K., Beg, M.S., Brower, S.T., Gade, T.P., et al. (2020) Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 38, 4317-4345. https://doi.org/10.1200/jco.20.02672 |
| [3] | Lee, M.S., Ryoo, B., Hsu, C., Numata, K., Stein, S., Verret, W., et al. (2020) Atezolizumab with or without Bevacizumab in Unresectable Hepatocellular Carcinoma (GO30140): An Open-Label, Multicentre, Phase 1b Study. The Lancet Oncology, 21, 808-820. https://doi.org/10.1016/s1470-2045(20)30156-x |
| [4] | Finn, R.S., Qin, S., Ikeda, M., Galle, P.R., Ducreux, M., Kim, T., et al. (2021) Imbrave150: Updated Overall Survival (OS) Data from a Global, Randomized, Open-Label Phase III Study of Atezolizumab (atezo) + Bevacizumab (bev) versus Sorafenib (sor) in Patients (pts) with Unresectable Hepatocellular Carcinoma (HCC). Journal of Clinical Oncology, 39, 267-267. https://doi.org/10.1200/jco.2021.39.3_suppl.267 |
| [5] | Qin, S., Ren, Z., Feng, Y., Yau, T., Wang, B., Zhao, H., et al. (2021) Atezolizumab Plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label Imbrave150 Study. Liver Cancer, 10, 296-308. https://doi.org/10.1159/000513486 |
| [6] | Li, D., Toh, H.C., Merle, P., Tsuchiya, K., Hernandez, S., Verret, W., et al. (2022) Atezolizumab Plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the Imbrave150 Randomized Clinical Trial. Liver Cancer, 11, 558-571. https://doi.org/10.1159/000525671 |
| [7] | Galle, P.R., Finn, R.S., Qin, S., Ikeda, M., Zhu, A.X., Kim, T., et al. (2021) Patient-Reported Outcomes with Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma (Imbrave150): An Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology, 22, 991-1001. https://doi.org/10.1016/s1470-2045(21)00151-0 |
| [8] | Gao, X., Zhao, R., Ma, H. and Zuo, S. (2023) Efficacy and Safety of Atezolizumab Plus Bevacizumab Treatment for Advanced Hepatocellular Carcinoma in the Real World: A Single-Arm Meta-Analysis. BMC Cancer, 23, Article No. 635. https://doi.org/10.1186/s12885-023-11112-w |
| [9] | Villanueva, A. (2019) Hepatocellular Carcinoma. New England Journal of Medicine, 380, 1450-1462. https://doi.org/10.1056/nejmra1713263 |
| [10] | Qin, S., Chen, M., Cheng, A., Kaseb, A.O., Kudo, M., Lee, H.C., et al. (2023) Atezolizumab Plus Bevacizumab versus Active Surveillance in Patients with Resected or Ablated High-Risk Hepatocellular Carcinoma (Imbrave050): A Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet, 402, 1835-1847. https://doi.org/10.1016/s0140-6736(23)01796-8 |
| [11] | 孙惠川, 谢青, 荚卫东, 等. 肝癌转化治疗中国专家共识(2021版) [J]. 中国实用外科杂志, 2021, 41(6): 618-632. |
| [12] | Kudo, M., Aoki, T., Ueshima, K., Tsuchiya, K., Morita, M., Chishina, H., et al. (2023) Achievement of Complete Response and Drug-Free Status by Atezolizumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-of-Concept Study. Liver Cancer, 12, 321-338. https://doi.org/10.1159/000529574 |
| [13] | Shimose, S., Iwamoto, H., Shirono, T., Tanaka, M., Niizeki, T., Kajiwara, M., et al. (2023) The Impact of Curative Conversion Therapy Aimed at a Cancer‐free State in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab. Cancer Medicine, 12, 12325-12335. https://doi.org/10.1002/cam4.5931 |
| [14] | Miyata, T., Sugi, K., Horino, T., Ono, A., Tagayasu, Y., Nomoto, D., et al. (2023) Conversion Surgery after Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis after Hepatocellular Carcinoma Rupture. Anticancer Research, 43, 943-947. https://doi.org/10.21873/anticanres.16239 |
| [15] | Fukunaga, A., Takata, K., Itoh, S., Yamauchi, R., Tanaka, T., Yokoyama, K., et al. (2022) Complete Tumor Necrosis Confirmed by Conversion Hepatectomy after Atezolizumab-Bevacizumab Treatment for Advanced-Stage Hepatocellular Carcinoma with Lung Metastasis. Clinical Journal of Gastroenterology, 16, 224-228. https://doi.org/10.1007/s12328-022-01744-z |
| [16] | 肝癌新辅助治疗中国专家共识协作组, 中国研究型医院学会消化外科专业委员会, 中国抗癌协会肝癌专业委员会. 肝癌新辅助治疗中国专家共识(2023版) [J]. 中华外科杂志, 2023, 61(12): 1035-1045. |
| [17] | 夏永祥, 张峰, 李相成, 等. 原发性肝癌10,966例外科治疗分析[J]. 中华外科杂志, 2021, 59(1): 6-17. |
| [18] | Abdelrahim, M., Esmail, A., Umoru, G., Westhart, K., Abudayyeh, A., Saharia, A., et al. (2022) Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report. Current Oncology, 29, 4267-4273. https://doi.org/10.3390/curroncol29060341 |
